Research Article

Amaranthus mangostanus Inhibits the Differentiation of Osteoclasts and Prevents Ovariectomy-Induced Bone Loss

Yeon-Hui Jeong, Haeng Jeon Hur, Ae Sin Lee, Sang Hee Lee, and Mi Jeong Sung

Research Group of Natural Materials and Metabolism, Food Functionality Research, Korea Food Research Institute, Jeollabuk-do, Republic of Korea

Correspondence should be addressed to Mi Jeong Sung; dulle5@kfri.re.kr

Received 27 August 2019; Revised 9 December 2019; Accepted 31 December 2019; Published 7 February 2020

Academic Editor: Filippo Fratini

Copyright © 2020 Yeon-Hui Jeong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Bone homeostasis is dynamically balanced between bone forming osteoblasts and bone resorbing osteoclasts. Osteoclasts play an important role in bone destruction and osteoporosis, and they are derived from monocyte/macrophages in response to macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor κB (NF-κB) ligand (RANKL). Amaranthus mangostanus L. (AM) is a plant with powerful antioxidant and other biological activities including anti-inflammatory, anti-diabetic, and antihyperlipidemic effects. However, its effects on bone health are unknown. In this study, we explored whether AM could affect RANK-mediated osteoclastogenesis. AM significantly suppressed RANKL-induced osteoclast differentiation and expression of osteoclast-specific genes, TRAP, cathepsin K, NF-activated T-cells (NFATc1), and Dc-stamp in RAW 264.7 cells. Moreover, AM significantly inhibited extracellular signal-regulated kinase (ERK), Akt, and NF-κB signaling pathways in RAW 264.7 cells. In addition, AM preserved ovariectomy-induced bone loss in mice. Taken together, our results suggest that AM might be a potential candidate for the treatment of postmenopausal osteoporosis.

1. Introduction

Osteoporosis is a metabolic bone disease associated with low bone mass and microarchitectural failure of bone and increased risk of bone fractures. It develops mainly in postmenopausal women and increases their risk of bone fractures [1, 2]. Bone homeostasis is dynamically balanced between bone-forming osteoblasts and bone-resorbing osteoclasts [3]. Osteoclasts are large, multinucleated cells derived from monocyte/macrophage lineage cells in response to macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor κB (NF-κB) ligand (RANKL) [4, 5]. Binding of RANKL to RANK is a key factor for osteoclast differentiation and functions, and the resulting complex leads to the recruitment tumor necrosis factor (TNF) receptor-associated factors (TRAFs) and activates downstream signaling pathways, mainly NF-κB, mitogen-activated protein kinase (MAPK), and AKT. Furthermore, it activates transcription factors such as nuclear factor of activated T cells (NFATc1) and c-fos to induce osteoclastogenesis [6–8].

Estrogen has an osteoprotective effect on bone remodeling, inhibits RANKL, and stimulates osteoblast to secrete osteoprotegerin (OPG), which competes with RANKL to suppress osteoclast differentiation [9, 10]. However, deficiency of estrogen after menopause results in increased osteoclastogenesis and decreased osteogenesis, which induces rapid bone loss and progression of osteoporosis [11]. Therefore, targeting RANKL-stimulated osteoclastogenesis may be a novel, alternative approach for postmenopausal osteoporosis treatment.

Considerable evidence shows that plant-derived natural products and traditional foods can promote bone mass and decrease bone fracture by suppressing osteoclastogenesis postmenopausally [12]. Edible Amaranth (Amaranthus mangostanus L., AM), known as “bireum” in Korea, is widely cultivated in Asia owing to its fast growth and nutritious
value and belongs to the family Amaranthaceae [13, 14]. Amaranth is a plant with potent antioxidant capacity, and it also contains bioactive compounds such as β-carotene, polyphenol, anthocyanins, and lutein [15]. In addition, amaranth has recently been demonstrated to possess various biological activities such as anti-inflammatory, antidiabetic, and antihyperlipidemic activities in vivo [16–19]. However, the effects of AM on bone health have not been elucidated. Therefore, we sought to characterize the effects of AM on osteoclastogenesis and explore its underlying mechanisms in RAW 264.7 cells. Furthermore, we investigated the preventive and therapeutic effects of AM on an ovariectomy (OVX-) induced bone loss in mice.

2. Materials and Methods

2.1. Reagents. RANKL was obtained from R&D Systems (Minneapolis, MN, USA). Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), and penicillin/streptomycin were purchased from W gentle (Daegu, Korea). Cell medium: minimum essential-α (α-MEM) was purchased from Gibco (USA). The tartrate-resistant acid phosphatase (TRAP) staining kit was obtained from Sigma-Aldrich. Primary antibodies against total and phospho-extracellular signal-regulated kinase (ERK), c-Jun N-terminal (JNK), p38, AKT, p-65, and NF-kB inhibitor-α (IκB) were purchased from Cell Signaling Technology (Beverly, MA, USA). NFATc1 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

2.2. Preparation of AM Extract. Dried AM was obtained from a local market in Korea, and the dried material was extracted (1:10 w/v) with 50% ethanol by shaking for 24 h at 20–25°C. The extract was collected using a filter paper (Whatman, USA) and vacuum evaporated. The supernatant was freeze-dried and stored at −80°C in a deep freezer. Major compounds present in the AM extract were analyzed using UPLC-MS (1290 Infinity II, USA; AB SCIEX, TripleTOF® 5600 plus, Agilent, USA) (Figure 1).

2.3. Analysis of AM Extracts Using LS-MS. To analyze and identify flavonoids present in the AM extract, the UPLC-MS system was used. The UPLC-MS study (1290 Infinity II, USA; AB SCIEX, TripleTOF® 5600 plus, Agilent, USA) was conducted with a YMC-Triart C18 column (4.6 mm × 250 mm, 5 μm, YMC Korea, Seongnam, Korea), and 0.1% formic acid in DW (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B) were used as the mobile phases. The mobile phase B concentration was 25% at 0 min, 40% at 25 min, and 90% at 30 min. Electrospray ionization (ESI) was performed in the negative-ion mode. The desolvation temperature was 400°C, and the other temperatures were modified slightly from those described previously [20].

2.4. Cell Culture, Differentiation of Osteoclasts, and TRAP Activity. RAW 264.7 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in DMEM supplemented with 10% FBS at 37°C. RAW 264.7 cells were plated in a 48-well plate at a density of 2 × 10⁴ cells/well. Osteoclast differentiation was induced by incubating the cells with M-CSF and RANKL in the presence or absence of various concentrations of AM. After 4 days, the cells were fixed and stained with TRAP solution, and then the TRAP-positive multinucleated cells containing three or more nuclei were considered osteoclasts and counted.

2.5. Cell Viability. The effect of AM on cell viability was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma). Cells were plated in a 96-well plate (1 × 10⁴ cells/well), and after 4 days of incubation, the cells were treated with varying concentrations of AM and then 0.5 mg/mL MTT solution was added to each well, followed by further incubation for 3 h at 37°C. The purple formazan crystals formed in the live cells were dissolved with dimethyl sulfoxide (DMSO), and the absorbance of the resultant solution was measured at 450 nm using an enzyme-linked immunosorbent assay (ELISA) reader (Molecular Devices, CA, USA).

2.6. RT-PCR Analysis. We evaluated the RANKL-induced expression of osteoclast-related genes using reverse transcription-polymerase chain reaction (RT-PCR). Briefly, total RNA was extracted using a QIAGEN mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol. Real-time quantitative PCR (qPCR) was performed using the iTaq Universal SYBR Green I Supermix (Bio-Rad, Hercules, CA, USA) according to the supplier’s protocol. The mRNA expression levels were normalized to those of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression. The PCR primer sequences used were as follows: NEATc1, sense: 5′-CGG TTG CCT CCA GAA AAC GTA A’-3′ and antisense: 5′-TTG GGG ATG CAT CCG AA’-3′; and GAPDH, sense: 5′-CAG TAG CCA CGC TTC CTG CTA TCC C’-3′ and antisense: 5′-ACT GGG TCT TGA GCA TTT CC-3′; TRAP, sense: 5′-GGG GCC AGG GAG GAC TAC T-3′ and antisense: 5′-CCC ACT CAG CAC ATA GCC CC’-3′; DC-stamp, sense: 5′-TAT CTG CAT TAT CCG CTC A’-3′ and antisense: 5′-AGA ATA ATA CTG AGA GGA ACC CA’-3′; and GAPDH, sense: 5′-AAA TGG TGA AGC TCG CTC TG-3′ and antisense: 5′-TGA AGG GGT CGT TGA TGG-3′.

2.7. Western Blot Analysis. To further corroborate the effects of the extract on osteoclast-related genes, protein levels were examined using Western blot analysis. Briefly, the whole cells were washed with PBS and lysed in ice-cold radio-immunoprecipitation assay (RIPA) buffer (40 mM HEPES (pH 7.4), 120 mM sodium chloride (NaCl), 1 mM ethylendiaminetetraacetic acid (EDTA), 50 mM sodium fluoride (NaF), 1.5 mM sodium vanadate (Na₃VO₄), 10 mM β-glycerophosphate, and 1% Triton X-100) supplemented with a protease and phosphatase inhibitor cocktail. Cell lysates were centrifuged at 13,000 ×g at 4°C for 15 min. To
confirm the translocation of p65, nuclear and cytoplasmic proteins were extracted using nuclear extract kit (Active Motif Co., Carlsbad, CA, USA), according to the manufacturer’s instructions. Equal amounts of protein were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose (NC) membranes. The membranes were blocked with 5% skim milk for 1 h and incubated overnight with primary antibodies at 4°C and then with horseradish peroxidase-conjugated secondary anti-mouse or anti-rabbit IgG (1:1,000, Santa Cruz Biotechnology Inc.) for 1 h. Signals were detected using a chemiluminescence reagent (Amer sham Bioscience, Piscataway, NJ, USA).

2.8. Animals and Ovariectomy. This animal study protocol was approved by the Institutional Animal Care and Use Committee of the Korea Food Research Institute (KFRI: KFRI-M-17047). Thirty ICR female mice (8 weeks old) were obtained from Orient-Bio Korea (Seoul, Korea) and were housed under controlled conditions at a temperature of 22–26°C on a 12 h light/dark cycle. All the mice were divided into three groups, and two group were subjected to ovariectomies, whereas one group underwent bilateral surgery (SHAM, n = 10). Two weeks later, the 20 OVX rats were body-weight matched and randomly divided into the vehicle-treated OVX (OVX) and AM-treated OVX (AM, 5 g/kg in the diet) groups. AM was suspended in distilled water while the diets were prepared by mixing each of the above-specified components with 1 kg of AIN 93M powdered diet (Dyets Inc., Bethlehem, PA, USA). Mice in the SHAM and OVX groups were fed a soy-free control diet and their body weight was measured weekly. The mice were subsequently euthanized and blood samples were collected via heart puncture and stored at −70°C for biochemical analysis. The femurs were excised and fixed in 4% paraformaldehyde at 4°C for bone structural parameter determination.

2.9. Serum Biochemical Assay. Serum total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) levels were determined using commercial enzyme kits (Asan Pharmaceuticals, Hwasung, Korea). Low-density lipoprotein cholesterol (LDL-C) levels were calculated as follows: LDL-C = TC − HDL-C − TG/5.

2.10. Microcomputed Tomography (μCT) Scanning. The fixed femurs were analyzed using a microcomputed tomography (μCT) scanner system (SkyScan 1076, Bruker, Germany). The scanning procedure was set at 18 μm and exposures were performed at 100 kV, 100 mA, and 1770 ms/frame. The CT images were scanned and analyzed using the relevant software (CT Analyzer V 1.11.0.0, Skyscan, Kontich, Belgium), and the two-dimensional (2D) and 3D images were obtained for visualization and analysis. The following bone morphometric parameters were evaluated, bone volume to tissue volume ratio (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp), using images acquired from a CT-AN 1.13 instrument (Bruker, Germany). The scan analysis operator was blinded to the specific treatments associated with each specimen.

2.11. Statistical Analysis. In vitro and in vivo data are presented as means ± standard error of the mean (SEM). The results were analyzed using a one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test using the Graphpad Prism software version 6.05 (Graphpad Software Inc., La Jolla, CA, USA). Differences between groups were considered significant at *p* < 0.05.

3. Results

3.1. AM Is Not Cytotoxic to RAW 264.7 Cells. To evaluate the effects of AM on cell viability, we determined its cytotoxicity against RAW 264.7 cells and found that it had no significant effect on the viability of these cells (Figure 2(a)).

3.2. AM Inhibits RANKL-Induced Osteoclastogenesis in RAW 264.7 Cells. To determine the effects of AM on osteoclastogenesis, RAW 264.7 cells were incubated with RANKL in presence or absence of various concentrations of AM.
3. AM Suppresses RANKL-Induced Osteoclast-Mediated Genes Expression. RANKL has been shown to induce the expression of osteoclast differentiation-related genes including NFATc1, TRAP, cathepsin K, and Dc-stamp. Therefore, to investigate the effects of AM on osteoclastogenesis, we evaluated RANKL-induced mRNA expression of these osteoclast-related genes using RT-qPCR. The results showed that AM decreased the expression levels of these genes in a dose-dependent manner (Figures 3(a) and 3(c)). To further confirm the effect of AM on the mRNA expression of NFATc, we also measured its protein level using immunoblot analysis. AM treatment inhibited RANKL-induced NFATc1 protein levels in a dose-dependent manner (Figure 3(b)).

3.4. AM Inhibits RANKL-Induced Activation of MAPKs, Akt, and NF-κB Pathways. RANKL-stimulated osteoclastogenesis is mediated by signaling pathways such as MAPKs, Akt, and NF-κB [21]. To investigate the effect of AM on RANKL-stimulated signaling pathways mediating osteoclast differentiation in RAW 264.7 cells, we determined the phosphorylation of MAPKs (ERK, JNK, and p38), Akt, and NF-κB using immunoblot analysis. Treatment of RAW 264.7 cells with RANKL dramatically phosphorylated ERK, JNK, p38 MAPKs, and Akt, as well as NF-κB signaling pathway (p-65 and IκB degradation) molecules. AM significantly inhibited RANKL-induced ERK and Akt activation in a dose-dependent manner. However, phosphorylated p38 and IκB MAPKs did not significantly change (Figure 4(a)). AM also largely suppressed the RANKL-induced NF-κB signaling pathway (Figure 4(b)). Moreover, AM attenuated RANKL-induced translocation of p65 from the cytosol to the nucleus (Figure 4(c)).

RANKL-treated cells differentiated into TRAP-positive multinucleated osteoclasts, and AM treatment decreased this effect in a dose-dependent manner (Figures 2(b) and 2(c)).
Figure 3: *Amaranthus mangostanus* (AM) suppressed receptor activator of nuclear factor-κB (NF-κB) ligand- (RANKL-) induced expression of osteoclast-specific genes. (a)–(d) RAW 264.7 cells were cultured with RANKL (50 ng/mL) at various concentrations for 4 days, and osteoclast-specific genes (cathepsin K, TRAP, Dc-stamp, and nuclear factor of activated T-cells (NFATc1)) were analyzed using real-time polymerase chain reaction (PCR). RNA expression levels were normalized to expression levels of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (e) RAW 264.7 cells were cultured with RANKL (50 ng/mL) with various concentrations for 4 days and osteoclast-specific gene NFATc1 was analyzed using Western blotting; n = 3; *p < 0.05 compared with control group, and *p < 0.05 compared with RANKL treatment group.

Figure 4: Continued.
3.5. AM Inhibits the Body, Fat, Liver, and Uterine Weight in OVX-Induced Mice. AM was further evaluated for its effects on osteoporosis. All three groups of rats showed similar initial body weights, whereas the final body weight of the OVX group was dramatically higher than that of the SHAM group. However, the mean final body weight of the AM-treated group was significantly reduced, suggesting that AM inhibited the OVX-induced body weight gain. Furthermore, the fat and liver weight of the OVX group was considerably greater than that of the SHAM group; however, that of the AM group was significantly reduced. Furthermore, the uterine weight of the OVX group was reduced more than that of the SHAM group, but no change was observed in the uterine weight of the AM group (Table 1).

3.6. AM Inhibits the Lipid Metabolism in OVX-Induced Mice. TG, TC, and LDL levels were significantly higher in the OVX mice than they were in the SHAM mice, whereas the levels were lower in the AM group than they were in the OVX mice. In addition, the group supplemented with AM exhibited slightly higher HDL levels than those of the OVX group (Figure 5).

3.7. AM Inhibits the Bone Loss in OVX-Induced Group In Vivo. To evaluate the effect of AM on OVX-induced bone deterioration using μCT and hematoxylin and eosin (H&E) staining of the distal femur of the mice. First, the 3D images revealed differences in the trabecular microarchitecture in the various groups. There was considerable deterioration of the trabecular bone of the OVX mice, whereas the AM-treated mice exhibited significant inhibition of OVX-induced deterioration of the bone structure (Figure 6(a)). The bone-morphometric parameters examined were the BV/TV, Tb.N, Tb.Th, and Tb.Sp. Quantification of the trabecular bone response found that the OVX group had decreased BV/TV and Tb.N and increased Tb.Sp compared with values of the SHAM group. Furthermore, AM increased the BV/TV and Tb.N and reduced the Tb.Sp compared to those of the OVX mice (Figures 6(c)–6(f)). However, the level of the Tb.Th was not different among the groups. Furthermore, the H&E staining shows that the AM groups exhibited a more significant preservation of the microtrabecular bone than the OVX groups did (Figure 6(b)).

4. Discussion

Osteoporosis is a “silent” disease, which commonly causes no symptoms until a fracture occurs [22]. Osteoporotic fractures are one of the most dangerous occurrences in patients and can cause further disability and early mortality. Moreover, it leads to huge economic cost to society. Bone homeostasis is a dynamic process regulated by bone formation and resorption mediated by osteoblastic and osteoclastic activities. However, an imbalance in these processes such as excessive bone resorption caused by enhanced osteoclastogenesis could cause bone-associated diseases including osteoporosis and bone metastasis [23]. Therefore, targeting the downregulation of osteoclastic signals as an alternative treatment strategy for osteoporosis is useful.

Osteoclasts are large, multinucleated cells involved in bone resorption, and they are derived when hematopoietic progenitor differentiates mononuclear TRAP-positive pre-osteoclast and fuses the multinucleated mature osteoclasts [23]. AM inhibited TRAP activity and the formation
of TRAP-positive multinucleated osteoclasts and did not cause any cytotoxicity in RAW 264.7 cells (Figure 2). These findings suggest that AM inhibited osteoclastogenesis.

RANKL has a crucial role in osteoclastogenesis, and its binding to RANK stimulates TNF receptor-associated factor 6 (TRAF6), which activates downstream signaling pathways such as MAPKs, Akt, and NF-κB involved in osteoclast differentiation [24–26]. MAPKs including ERK, JNK, and p38 pathways phosphorylated and the generated signals are transduced to the nucleus for gene transcription. Phosphorylation of ERK reduces osteoclast differentiation. Inhibition of the ERK pathway decreases osteoclast formation [27]. The present results showed that AM suppressed phosphorylation of ERK and the activation of the NF-κB pathway was associated with five member proteins such as RelA (p65), RelB, cRel, NF-κB1 (p50), and NF-κB (p52).

One study reported that NF-κB p50/p52 knockout mice exhibited severe osteoporosis because osteoclasts did not form [24]. In resting cells, NF-κB proteins are in the cytoplasm combined with the inhibitory IκBα [28]. Following the binding of RANKL to RANK, IκBα is phosphorylated and degraded, and p65/p50 dimers are translocated to the nucleus for gene transcription [25]. These results reveal that AM reduced RANKL-induced phosphorylation of p65 and blocked the degradation of IκB. In addition, RANKL activates the Akt signal pathway by interacting with TRAF6 and c-Src. These results show that AM reduced RANKL-induced phosphorylation of Akt (Figure 4), suggesting that AM suppressed osteoclastogenesis by suppressing RANKL-induced ERK, NF-κB, and Akt signaling pathways.

NFATc1 is considered a key transcription factor of NF-κB, ERK, and Akt signaling pathways in osteoclastogenesis [29]. This transcription factor is essential in regulating osteoclast-specific genes such as TRAP, cathepsin K, and Dc-stamp [30]. Our results showed that AM significantly inhibited the expression of NFATc1 and the downstream gene expression.

OVX mice are a well-known experimental model of postmenopausal osteoporosis associated with estrogen deficiency and exhibit a similar reduction in the BMD and change of microarchitecture to that shown in humans [31]. Furthermore, excessive activation of osteoclastogenesis is a key factor in the pathogenesis of osteoporosis [32]. Thus, inhibiting BMD and bone fracture by suppressing osteoclastogenesis may be a useful strategy for postmenopausal osteoporosis treatment. Several bodies of evidence demonstrated that preservation of trabecular bone microarchitecture improved, reducing the fracture risk and bone strength [33].

Figure 5: *Amaranthus mangostanus* (AM) improves ovariectomy-induced dyslipidemia in mice. (a) Triglycerides (TG) and (b) total cholesterol (TC). (c) High-density lipoprotein cholesterol (HDL-C). (d) Low-density lipoprotein cholesterol (LDL-C). #p < 0.05 and *p < 0.05 compared to SHAM and OVX groups, respectively.
Figure 6: Continued.
Our study showed that AM suppresses osteoclastogenesis in vitro (Figure 2) and administration of AM significantly reserved the OVX-induced trabecular bone parameters in vivo (Figure 6). These results suggest that AM prevented bone mass and trabecular bone by suppressing osteoclastogenesis. In addition, postmenopausal women with deficiency of estrogens show obesity, hyperlipidemia, and insulin resistance [34]. In our previous study, we reported that OVX mice exhibited increased body weight, hyperlipidemia, and visceral fat accumulation [35]. In the present study, the OVX mice showed increased body, fat, and liver weight compared to the SHAM mice. Treatment with AM protected mice against the OVX-induced increase in body, liver, and fat weight (Table 1). Furthermore, AM also reduced the serum LDL-C and TG in OVX mice (Figure 5). These results suggest that AM prevented obesity-mediated metabolic diseases in OVX mice.

Recently, it was shown that an extract of AM containing β-carotene, polyphenol, anthocyanin, and lutein has various biological activities such as antioxidant and anti-inflammatory effects [15]. In this study, we evaluated one of the compounds of AM extract, kaempferol. Several studies have shown that kaempferol inhibits osteoclastic bone resorption and stimulates osteogenic differentiation in vitro [36, 37]. Moreover, kaempferol attenuated bone loss in a rat model of OVX-induced osteopenia [38]. Therefore, it was considered that kaempferol present in the AM extract is one of the bioactive compounds responsible for the antiosteoporotic effects.

In the present study, we, for the first time, provide evidence that AM effectively suppressed RANKL-induced osteoclast differentiation by inhibiting the NF-κB and MAPK signaling pathways in vitro. In addition, AM prevented OVX-induced bone loss in vivo. Thus, our finding...
results suggest that AM is a promising alternative treatment candidate for osteoporosis.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare that there are no conflicts of interest.

Acknowledgments
This study was supported by the Korea Food Research Institute and National Research Council of Science and Technology (NST) grant from the Korean Government (MSIP, no. CAP-15-09-KIMS).

References

[1] C. Cooper, S. Westlake, N. Harvey, K. Javaid, E. Dennison, and M. Hanson, "Review: developmental origins of osteoporotic fracture," *Osteoporosis International*, vol. 17, no. 3, pp. 337–347, 2006.

[2] E. F. Eriksen, A. Diez-Perez, and S. Boonen, "Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review," *Bone*, vol. 58, pp. 126–135, 2014.

[3] X. Wu, Z. Li, Z. Yang et al., "Caffeic acid 3,4-dihydroxyphenethyl ester suppresses receptor activator of NF-κB ligand-induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca²⁺-nuclear fact," *Journal of Bone and Mineral Research*, vol. 27, no. 6, pp. 1298–1308, 2012.

[4] C. Li, Z. Yang, Z. Li et al., "Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways," *Journal of Bone and Mineral Research*, vol. 26, no. 3, pp. 644–656, 2011.

[5] D. V. Novack, "Role of NF-κB in the skeleton," *Cell Research*, vol. 21, no. 1, pp. 169–182, 2011.

[6] B. G. Darnay, J. Ni, P. A. Moore et al., "Activation of NF-kappB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappB-inducing kinase. Identification of a novel TRAF6 interaction motif," *Journal of Biological Chemistry*, vol. 274, no. 43, pp. 7724–7731, 1999.

[7] G. Pearson, F. Robinson, T. B. Gibson et al., "Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions," *Endocrine Reviews*, vol. 22, no. 2, pp. 153–183, 2011.

[8] H. Takayanagi, S. Kim, T. Koga et al., "Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts," *Developmental Cell*, vol. 3, no. 6, pp. 889–901, 2002.

[9] A. Janas and J. Polwarczna, "Opioid receptor agonists may favorably affect bone mechanical properties in rats with estrogen deficiency-induced osteoporosis," *Naunyn-Schmiedeberg's Archives of Pharmacology*, vol. 390, no. 2, pp. 175–185, 2017.

[10] Y. Zhou, Z.-L. Zhu, X.-X. Guan, W.-W. Hou, and H.-Y. Yu, "Reciprocal roles between caffeine and estrogen on bone via differently regulating cAMP/PKA pathway: the possible mechanism for caffeine-induced osteoporosis in women and estrogen’s antagonistic effects," *Medical Hypotheses*, vol. 73, no. 1, pp. 83–85, 2009.

[11] L. A. Fraser, K. N. Vogt, R. Adachi, and L. Thabane, "Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis," *Therapeutics and Clinical Risk Management*, vol. 7, pp. 157–166, 2011.

[12] S. Y. Bu, M. Lerner, B. J. Stoecker et al., "Dried plum polyphenols inhibit osteoclastogenesis by downregulating NFATc1 and inflammatory mediators," *Calcified Tissue International*, vol. 82, no. 6, pp. 475–488, 2008.

[13] H.-L. Fan and W. Zhou, "Screening of amaranth cultivars (Amaranthus mangostanus L.) for cadmium hyperaccumulation," *Agricultural Sciences in China*, vol. 8, no. 3, pp. 342–351, 2009.

[14] Z. Long, X. Kong, C. Zhang et al., "Stability of hydroperoxide lyase activity from Amaranthus tricolor (Amaranthus mangostanus L.) leaves: influence of selected additives," *Journal of the Science of Food and Agriculture*, vol. 90, no. 5, pp. 729–734, 2010.

[15] S. Han and B. Xu, "Bioactive components of leafy vegetable edible amaranth (Amaranthus mangostanus L.) as affected by home cooking manners," *American Journal of Food Science and Technology*, vol. 2, no. 4, pp. 122–127, 2014.

[16] B. S. Ashok Kumar, K. Lakshman, K. N. Jayaveeta et al., "Antidiabetic, anti hyperlipidemic and antioxidant activities of methanolic extract of Amaranthus viridis Linn in alloxan induced diabetic rats," *Experimental and Toxicologic Pathology*, vol. 64, no. 1-2, pp. 75–79, 2012.

[17] H. K. Kim, M. J. Kim, H. Y. Cho, E.-K. Kim, and D. H. Shin, "Antioxidative and anti-diabetic effects of amaranth (Amaranthus esculentus) in streptozotocin-induced diabetic rats," *Cell Biochemistry and Function*, vol. 24, no. 3, pp. 195–199, 2006.

[18] A. Montoya-Rodriguez, E. G. de Mejia, V. P. Dia, C. Reyes-Moreno, and J. Milán-Carrillo, "Extrusion improved the anti-inflammatory effect of amaranth (Amaranthus hypochondriacus) hydrolysates in LPS-induced human THP-1 macrophage-like and mouse RAW 264.7 macrophages by preventing activation of NF-κB signaling," *Molecular Nutrition & Food Research*, vol. 58, no. 5, pp. 1028–1041, 2014.

[19] D. H. Shin, H. J. Heo, Y. J. Lee, and H. K. Kim, "Amaranth squalene reduces serum and liver lipid levels in rats fed a cholesterol diet," *British Journal of Biomedical Science*, vol. 61, no. 1, pp. 11–14, 2004.

[20] H. Lee, I. N. Oh, J. Kim et al., "Phenolic compound profiles and their seasonal variations in new red-phenotype head-forming chineses cabbages," *LWT*, vol. 90, pp. 433–439, 2018.

[21] H.-Y. Tsai, H.-Y. Lin, Y.-C. Fong et al., "Paeonol inhibits RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced bone loss by inhibiting ERK, p38 and NF-κB pathway," *European Journal of Pharmacology*, vol. 588, no. 1, pp. 124–133, 2008.

[22] S. Chen, G. Jin, K. M. Huang et al., "Lycorine suppresses RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo," *Scientific Reports*, vol. 5, no. 1, Article ID 12853, 2015.

[23] W. J. Boyle, W. S. Simonet, and D. L. Lacey, "Osteoclast differentiation and activation," *Nature*, vol. 423, no. 6937, pp. 337–342, 2003.
[24] G. Franzoso, L. Carlson, L. Xing et al., “Requirement for NF-
kappa B in osteoclast and B-cell development,” *Genes &
Development*, vol. 11, no. 24, pp. 3482–3496, 1997.

[25] S. Ghosh and M. Karin, “Missing pieces in the NF-kappaB
puzzle,” *Cell*, vol. 109, no. Suppl, pp. S81–S96, 2002.

[26] D. Stevenson, E. Schwarz, J. Carey et al., “Bone resorption in
syndromes of the Ras/MAPK pathway,” *Clinical Genetics*,
vol. 80, no. 6, pp. 566–573, 2011.

[27] M. Li, W. Wang, L. Geng et al., “Inhibition of RANKL-in-
duced osteoclastogenesis through the suppression of the ERK
signaling pathway by astragaloside IV and attenuation of
titanium-particle-induced osteolysis,” *International Journal of
Molecular Medicine*, vol. 42, no. 1, p. 675, 2018.

[28] S. E. Keating, G. M. Maloney, E. M. Moran, and A. G. Bowie,
“IRAK-2 participates in multiple toll-like receptor signaling
pathways to NFκB via activation of TRAF6 ubiquitination,”
*Journal of Biological Chemistry*, vol. 282, no. 46, pp. 33435–
33443, 2007.

[29] X. Chen, X. Zhi, P. Pan et al., “Matrine prevents bone loss in
ovariectomized mice by inhibiting RANKL-induced osteo-
clastogenesis,” *The FASEB Journal*, vol. 31, no. 11,
pp. 4855–4865, 2017.

[30] J.-Y. Kim, Y.-H. Cheon, K.-H. Yoon, M. S. Lee, and J. Oh,
“Parthenolide inhibits osteoclast differentiation and bone
resorbing activity by down-regulation of NFATc1 induction
and c-Fos stability, during RANKL-mediated osteoclasto-
genesis,” *BMB Reports*, vol. 47, no. 8, pp. 451–456, 2014.

[31] M. Spilmont, L. Léotoing, M.-J. Davicco et al., “Pomegranate
and its derivatives can improve bone health through de-
creased inflammation and oxidative stress in an animal model
of postmenopausal osteoporosis,” *European Journal of Nu-
trition*, vol. 53, no. 5, pp. 1155–1164, 2014.

[32] U. H. Lerner, “Bone remodeling in post-menopausal osteo-
porosis,” *Journal of Dental Research*, vol. 85, no. 7, pp. 584–
595, 2006.

[33] L. D. Carbonare, M. E. Arlot, P. M. Chavassieux, J. P. Roux,
N. R. Portero, and P. J. Meunier, “Comparison of trabecular
bone microarchitecture and remodeling in glucocorticoid-
induced and postmenopausal osteoporosis,” *Journal of Bone
and Mineral Research*, vol. 16, no. 1, pp. 97–103, 2001.

[34] F. Lizcano and G. Guzmán, “Estrogen deficiency and the
origin of obesity during menopause,” *BioMed Research In-
ternational*, vol. 2014, Article ID 757461, 11 pages, 2014.

[35] Y. H. Jeong, H. J. Hur, E. J. Jeon et al., “Honokiol improves
liver steatosis in ovariectomized mice,” *Molecules*, vol. 23,
no. 1, p. 194, 2018.

[36] J. L. Pang, D. A. Ricupero, S. Huang et al., “Differential activity
of kaempferol and quercetin in attenuating tumor necrosis
factor receptor family signaling in bone cells,” *Biochemical
Pharmacology*, vol. 71, no. 6, pp. 818–826, 2006.

[37] I. R. Kim, S. E. Kim, H. S. Baek et al., “The role of Kaempferol-
induced autophagy on differentiation and mineralization of
osteoblastic MC3T3-E1 cells,” *BMC Complementary and
Alternative Medicine*, vol. 16, no. 1, p. 333, 2016.

[38] B. Nowak, A. Matuszewska, A. Nikodem et al., “Oral ad-
ministration of kaempferol inhibits bone loss in rat model of
ovariectomy-induced osteopenia,” *Pharmacological Reports*,
vol. 69, no. 5, pp. 1113–1119, 2017.